Pages that link to "Q40571712"
Jump to navigation
Jump to search
The following pages link to Assessment of a small molecule melanocortin-4 receptor-specific agonist on energy homeostasis (Q40571712):
Displaying 11 items.
- Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction (Q28271756) (← links)
- The obesity pipeline: current strategies in the development of anti-obesity drugs (Q34578590) (← links)
- Functional evaluation of THIQ, a melanocortin 4 receptor agonist, in models of food intake and inflammation (Q34715986) (← links)
- Chronic HO-1 induction with cobalt protoporphyrin (CoPP) treatment increases oxygen consumption, activity, heat production and lowers body weight in obese melanocortin-4 receptor-deficient mice (Q35115604) (← links)
- Investigational therapies in the treatment of obesity (Q36543067) (← links)
- Recent progress toward nonpeptide ligands for the melanocortin-4 receptor (Q36729120) (← links)
- Disruption of Gpr45 causes reduced hypothalamic POMC expression and obesity (Q37217535) (← links)
- The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options (Q38115094) (← links)
- Enhanced anorexigenic signaling in lean obesity resistant syndecan-3 null mice (Q41527061) (← links)
- Central administration of metformin into the third ventricle of C57BL/6 mice decreases meal size and number and activates hypothalamic S6 kinase (Q47225253) (← links)
- Peptides and Peptidomimetics as Potential Antiobesity Agents: Overview of Current Status (Q64227581) (← links)